Medical
UK
Europe
NovoCure
$50.389876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$50.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.08 (0.16%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!
About
NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Employees
598
Headquarters
St. Helier, Jersey
Founded
2000
Market Cap
4.82B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
742.30K
High Today
$51.35
Low Today
$49.83
Open Price
$49.91
Volume
126.40K
52 Week High
$56.67
52 Week Low
$26.02
Collections
Medical
UK
Europe
Health
Cancer Prevention
Technology
2015 IPO
News
The Motley FoolMay 7
5 Key Takeaways From NovoCure's Big First-Quarter
Novocure (NASDAQ:NVCR), a fast-growing medical device company focused on cancer, reported its first-quarter results on May 2. NovoCure's stock has been red-hot over the last few years as it works to bring its innovative product -- a device called Optune that makes use of a new therapy called tumor treating fields -- to more patients who suffer from a deadly form of brain cancer called glioblastoma multiforme (GBM). Novocure's stock rose more than 8% on the day following the earnings announcement. What was...
Seeking AlphaMay 2
NovoCure Limited 2019 Q1 - Results - Earnings Call Slides
The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q1 earnings call. 1 14 Click to enlarge Notes:...
Yahoo FinanceMay 2
NovoCure: 1Q Earnings Snapshot
SAINT HELIER, Jersey (AP) _ NovoCure Ltd. (NVCR) on Thursday reported a loss of $12.2 million in its first quarter. The Saint Helier, Jersey-based company said it had a loss of 13 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 13 cents per share. The oncology drug developer posted revenue of $73.3 million in the period, falling short of Street forecasts. Three analysts surveyed by Zacks expected...
Price Paid on Robinhood
55% Higher
Right Now
52 Week Low
$26.02
Average Price Paid
$32.43
52 Week High
$56.67
Earnings
-$0.23
-$0.19
-$0.15
-$0.11
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 25, Pre-Market